The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The role of menin inhibitors in the treatment of AML
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the use of menin inhibitors for the treatment of acute myeloid leukemia (AML), drawing focus on DSP-5336. Dr Daver first highlights the safety and efficacy of these agents and further comments on their role in the future treatment landscape of AML. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
